The importance of stem cells in the treatment of type 1 diabetes, type 2 diabetes and diabetes complications
The importance of stem cells in diabetology
DOI:
https://doi.org/10.12775/QS.2025.37.57420Keywords
stem cells, diabetes mellitus type 1, diabetes mellitus type 2, diabetic retinopathy, woundAbstract
Introduction and Purpose. Diabetes, characterized by hyperglycemia due to impaired insulin production or action, leads to significant complications like diabetic retinopathy (DR) and diabetic foot syndrome (DFS). Current treatments manage symptoms but do not fully address disease progression. Stem cells, with their regenerative potential and immunomodulatory properties, represent a promising avenue for treating diabetes and its complications. This study explores the use of stem cell therapy in managing type 1 and type 2 diabetes, DR, and DFS.
Material and Method. The study reviewed existing literature on the application of stem cells in diabetes treatment. More than 30 articles addressing these issues were analyzed. They were found using the PubMed search engine, and the time frame of these publications covered the last 20 years.
Results. Stem cells demonstrated significant potential in diabetes management. For type 1 diabetes, MSCs reduced inflammation, preserved pancreatic islet function, and decreased insulin requirements without major adverse effects. Pluripotent stem cells showed promise in islet transplantation, achieving stable glycemic control in clinical trials. In type 2 diabetes, stem cell therapy improved insulin sensitivity and reduced insulin dependency, with evidence of β-cell regeneration. Complications like diabetic foot ulcers and retinopathy also responded positively to stem cell treatments. MSCs improved wound healing by enhancing tissue regeneration and reducing inflammation, while retinal therapies showed promise in slowing disease progression and repairing damaged vasculature.
Conclusions. Stem cell therapies offer a promising approach for diabetes and its complications, particularly for regenerative applications in DR and DFS. While initial results are encouraging, further large-scale studies are needed to optimize protocols, assess long-term safety, and establish standardized clinical applications.
References
1. Chęciński M, Chęcińska K, Turosz N, et al. Autologous Stem Cells Transplants in the Treatment of Temporomandibular Joints Disorders: A Systematic Review and Meta-Analysis of Clinical Trials. Cells. 2022 Aug 30;11(17):2709. doi: 10.3390/cells11172709. PMID: 36078117; PMCID: PMC9454527.
2. Demir S, Nawroth PP, Herzig S, et al. Emerging Targets in Type 2 Diabetes and Diabetic Complications. Adv Sci (Weinh). 2021 Sep;8(18):e2100275. doi: 10.1002/advs.202100275. Epub 2021 Jul 28. PMID: 34319011; PMCID: PMC8456215.
3. Xiong J, Hu H, Guo R, et al. Mesenchymal Stem Cell Exosomes as a New Strategy for the Treatment of Diabetes Complications. Front Endocrinol (Lausanne). 2021 Apr 29;12:646233. doi: 10.3389/fendo.2021.646233. PMID: 33995278; PMCID: PMC8117220.
4. Mikłosz A, Chabowski A. Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus. J Clin Endocrinol Metab. 2023 Jul 14;108(8):1889-1897. doi: 10.1210/clinem/dgad142. PMID: 36916961; PMCID: PMC10348459.
5. Yu X, Liu P, Li Z, et al. Function and mechanism of mesenchymal stem cells in the healing of diabetic foot wounds. Front Endocrinol (Lausanne). 2023 Mar 16;14:1099310. doi: 10.3389/fendo.2023.1099310. PMID: 37008908; PMCID: PMC10061144.
6. Li XJ, Li CY, Bai D, et al. Insights into stem cell therapy for diabetic retinopathy: a bibliometric and visual analysis. Neural Regen Res. 2021 Jan;16(1):172-178. doi: 10.4103/1673-5374.286974. PMID: 32788473; PMCID: PMC7818871.
7. Habiba UE, Khan N, Greene DL, et al. Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes. Front Endocrinol (Lausanne). 2024 May 10;15:1380443. doi: 10.3389/fendo.2024.1380443. PMID: 38800472; PMCID: PMC11116613.
8. Zhou B, Zhou N, Jiang J, et al. Exosomal miR-25 from Mesenchymal stem cells inhibits T cells migration and Alleviates Type 1 diabetes mellitus by Targeting CXCR3 models. Gene. 2025 Feb 5;936:149098. doi: 10.1016/j.gene.2024.149098. Epub 2024 Nov 14. PMID: 39547359.
9. Utami A, Putra A, Wibowo JW, et al. Hypoxic secretome mesenchymal stem cells inhibiting interleukin-6 expression prevent oxidative stress in type 1 diabetes mellitus. Med Glas (Zenica). 2023 Aug 1;20(2). doi: 10.17392/1538-23. Epub ahead of print. PMID: 37300468.
10. Mićanović D, Stanisavljević S, Li H, et al. Mesenchymal Stem Cells from Mouse Hair Follicles Inhibit the Development of Type 1 Diabetes. Int J Mol Sci. 2024 May 29;25(11):5974. doi: 10.3390/ijms25115974. PMID: 38892159; PMCID: PMC11172537.
11. Khalil DY, Hussein RH, El-Kholy WM. Mesenchymal Stem Cell-Derived Exosomes Loaded with Selenium or Nano Selenium as a Novel Therapeutic Paradigm for Streptozotocin-Induced Type 1 Diabetes in Rats. Biology (Basel). 2024 Apr 11;13(4):253. doi: 10.3390/biology13040253. PMID: 38666865; PMCID: PMC11048049.
12. Jawale S. Intrapancreatic autologous stem cell therapy for type 1 diabetes - an experimental study. Ann Med Surg (Lond). 2023 Jul 28;85(9):4355-4371. doi: 10.1097/MS9.0000000000000837. PMID: 37663700; PMCID: PMC10473305.
13. Leão IS, Dantas JR, Araújo DB, et al. Evaluation of type 1 diabetes' partial clinical remission after three years of heterologous adipose tissue derived stromal/stem cells transplantation associated with vitamin D supplementation. Diabetol Metab Syndr. 2024 May 24;16(1):114. doi: 10.1186/s13098-024-01302-2. PMID: 38790009; PMCID: PMC11127374.
14. Wang S, Du Y, Zhang B, et al. Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. Cell. 2024 Oct 31;187(22):6152-6164.e18. doi: 10.1016/j.cell.2024.09.004. Epub 2024 Sep 25. PMID: 39326417.
15. Zang L, Li Y, Hao H, et al. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. Stem Cell Res Ther. 2022 May 3;13(1):180. doi: 10.1186/s13287-022-02848-6. PMID: 35505375; PMCID: PMC9066971.
16. Guan LX, Guan H, Li HB, et al. Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes. Exp Ther Med. 2015 May;9(5):1623-1630. doi: 10.3892/etm.2015.2339. Epub 2015 Mar 9. PMID: 26136869; PMCID: PMC4471780.
17. Bhansali A, Asokumar P, Walia R, et al. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. Cell Transplant. 2014;23(9):1075-85. doi: 10.3727/096368913X665576. PMID: 23561959.
18. Gao S, Zhang Y, Liang K, et al. Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes. Stem Cells Int. 2022 Aug 22;2022:8637493. doi: 10.1155/2022/8637493. PMID: 36045953; PMCID: PMC9424025.
19. Verdi J, Shirian S, Saleh M, et al. Mesenchymal Stem Cells Regenerate Diabetic Foot Ulcers: A Review Article. World J Plast Surg. 2022 Mar;11(1):12-22. doi: 10.52547/wjps.11.1.12. PMID: 35592239; PMCID: PMC9018029.
20. Armstrong DG, Tan TW, Boulton AJM, et al. Diabetic Foot Ulcers: A Review. JAMA. 2023 Jul 3;330(1):62-75. doi: 10.1001/jama.2023.10578. PMID: 37395769; PMCID: PMC10723802.
21. Deng H, Li B, Shen Q, et al. Mechanisms of diabetic foot ulceration: A review. J Diabetes. 2023 Apr;15(4):299-312. doi: 10.1111/1753-0407.13372. Epub 2023 Mar 9. PMID: 36891783; PMCID: PMC10101842.
22. Jiang P, Li Q, Luo Y, et al. Current status and progress in research on dressing management for diabetic foot ulcer. Front Endocrinol (Lausanne). 2023 Aug 17;14:1221705. doi: 10.3389/fendo.2023.1221705. PMID: 37664860; PMCID: PMC10470649.
23. Gupta GJ, Karki K, Jain P, et al. Autologous Bone Marrow Aspirate Therapy for Skin Tissue Engineering and Tissue Regeneration. Adv Wound Care (New Rochelle). 2017 Apr 1;6(4):135-142. doi: 10.1089/wound.2016.0704. PMID: 28451470; PMCID: PMC5385415.
24. Farabi B, Roster K, Hirani R, et al. The Efficacy of Stem Cells in Wound Healing: A Systematic Review. Int J Mol Sci. 2024 Mar 5;25(5):3006. doi: 10.3390/ijms25053006. PMID: 38474251; PMCID: PMC10931571.
25. O'Loughlin A, Kulkarni M, Vaughan EE, et al. Autologous circulating angiogenic cells treated with osteopontin and delivered via a collagen scaffold enhance wound healing in the alloxan-induced diabetic rabbit ear ulcer model. Stem Cell Res Ther. 2013;4(6):158. doi: 10.1186/scrt388. PMID: 24444259; PMCID: PMC4054999.
26. Mazini L, Rochette L, Admou B, et al. Hopes and Limits of Adipose-Derived Stem Cells (ADSCs) and Mesenchymal Stem Cells (MSCs) in Wound Healing. Int J Mol Sci. 2020 Feb 14;21(4):1306. doi: 10.3390/ijms21041306. PMID: 32075181; PMCID: PMC7072889.
27. Silva EA, Kim ES, Kong HJ, et al. Material-based deployment enhances efficacy of endothelial progenitor cells. Proc Natl Acad Sci U S A. 2008 Sep 23;105(38):14347-52. doi: 10.1073/pnas.0803873105. Epub 2008 Sep 15. PMID: 18794520; PMCID: PMC2567164.
28. Moustafa M, Bullock AJ, Creagh FM, et al. Randomized, controlled, single-blind study on use of autologous keratinocytes on a transfer dressing to treat nonhealing diabetic ulcers. Regen Med. 2007 Nov;2(6):887-902. doi: 10.2217/17460751.2.6.887. PMID: 18034628.
29. Tan ST, Aisyah PB, Firmansyah Y, et al. Effectiveness of Secretome from Human Umbilical Cord Mesenchymal Stem Cells in Gel (10% SM-hUCMSC Gel) for Chronic Wounds (Diabetic and Trophic Ulcer) - Phase 2 Clinical Trial. J Multidiscip Healthc. 2023 Jun 23;16:1763-1777. doi: 10.2147/JMDH.S408162. PMID: 37383529;
30. Sun X, Ying J, Wang Y, et al. Meta-analysis on autologous stem cell transplantation in the treatment of limb ischemic. Int J Clin Exp Med. 2015 Jun 15;8(6):8740-8. PMID: 26309525; PMCID: PMC4538153.
31. Matuszewski W, Bandurska-Stankiewicz E, Modzelewski R, et al. Diagnosis and treatment of diabetic retinopathy — historical overview. Clin Diabetol 2017; 6, 5: 182–188. DOI: 10.5603/DK.2017.0030.
32. Gaddam S, Periasamy R, Gangaraju R. Adult Stem Cell Therapeutics in Diabetic Retinopathy. Int J Mol Sci. 2019 Sep 30;20(19):4876. doi: 10.3390/ijms20194876. PMID: 31575089; PMCID: PMC6801872.
33. Chen Y, Yao G, Tong J, et al. MSC-Derived Small Extracellular Vesicles Alleviate Diabetic Retinopathy by Delivering miR-22-3p to Inhibit NLRP3 Inflammasome Activation. Stem Cells. 2024 Jan 13;42(1):64-75. doi: 10.1093/stmcls/sxad078. PMID: 37847598.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Monika Kamińska, Maria Jasiewicz, Magdalena Miernik-Skrzypczak, Aleksandra Spyra, Marta Malicka, Natalia Dąbrowska, Aleksandra Kozioł, Katarzyna Moczyróg

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 95
Number of citations: 0